Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

International Stem Cell Corp (ISCO)

International Stem Cell Corp (ISCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 570
  • Shares Outstanding, K 8,000
  • Annual Sales, $ 7,790 K
  • Annual Income, $ -130 K
  • 60-Month Beta 0.52
  • Price/Sales 0.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ISCO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $-0.04 on 03/28/24
  • Latest Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0550 +18.18%
on 04/03/24
0.1200 -45.83%
on 04/11/24
+0.0129 (+24.76%)
since 03/22/24
3-Month
0.0460 +41.30%
on 02/14/24
0.1295 -49.81%
on 01/25/24
-0.0545 (-45.61%)
since 01/24/24
52-Week
0.0460 +41.30%
on 02/14/24
0.1679 -61.29%
on 05/12/23
-0.1150 (-63.89%)
since 04/21/23

Most Recent Stories

More News
International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology...

ISCO : 0.0650 (-8.71%)
International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End Results

SAN DIEGO, CA / ACCESSWIRE / March 30, 2022 / International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology...

ISCO : 0.0650 (-8.71%)
International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease

CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company...

ISCO : 0.0650 (-8.71%)
Final Results for the year ended 31 December 2020

Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) (“4D”, the “Company” or, together with its subsidiaries, the “Group”), a pharmaceutical company leading...

LBPS : 1.6500 (+2.48%)
LBPSW : 0.0442 (-25.71%)
LGND : 71.00 (+1.59%)
ISCO : 0.0650 (-8.71%)
4D Pharma Appointments Paul Maier to the Board as Non-Executive Director

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of...

DDDD.LN : 16.660 (unch)
LGND : 71.00 (+1.59%)
ISCO : 0.0650 (-8.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes,...

See More

Key Turning Points

3rd Resistance Point 0.0757
2nd Resistance Point 0.0721
1st Resistance Point 0.0685
Last Price 0.0650
1st Support Level 0.0613
2nd Support Level 0.0577
3rd Support Level 0.0541

See More

52-Week High 0.1679
Fibonacci 61.8% 0.1213
Fibonacci 50% 0.1069
Fibonacci 38.2% 0.0926
Last Price 0.0650
52-Week Low 0.0460

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar